10X Genomics (TXG) Stock Jumps 4% on Cleveland Clinic Bladder Cancer Partnership

TLDR

• TXG stock rose 3.8% Wednesday after announcing a multi-year research partnership with Cleveland Clinic
• The collaboration focuses on bladder cancer biomarker discovery using 10X Genomics’ single cell and spatial analysis platforms
• Platforms involved include Flex Apex, Xenium, and the recently announced Atera
• Research will analyze tumor samples from advanced bladder cancer patients to study response to antibody-drug conjugate therapies
• Insiders sold $1.8 million worth of TXG stock over the past three months, with no insider buying reported

10X Genomics (TXG) stock climbed 3.8% on Wednesday after the company announced a multi-year research collaboration with Cleveland Clinic targeting bladder cancer.

10x Genomics, Inc., TXG

The stock was trading around $31.76 ahead of the announcement, with the move pushing it higher on the session.

The partnership centers on identifying biomarkers that could predict how patients respond to antibody-drug conjugate treatments — a growing area of cancer therapy.

The research will use 10X Genomics’ single cell and spatial analysis platforms, specifically Flex Apex, Xenium, and the recently launched Atera platform.

Tumor samples from patients with advanced bladder cancer will be examined. The goal is to understand the tumor microenvironment, immune cell infiltration, and how cancer cells respond or resist certain therapies.

The study will combine single-cell transcriptomic profiling, spatial gene expression data, and protein measurements to build a comprehensive clinical dataset.

Timothy Chan, MD, PhD, Chair of the Department of Cancer Sciences at Cleveland Clinic, called it “promising work” that could “shed new light into the mechanisms underlying therapeutic response in a number of major cancer types.”

What the Research Involves

The collaboration goes beyond bladder cancer in its broader ambitions. 10X Genomics says the partnership is part of its wider effort to work with research institutions and generate evidence that could support future diagnostic applications across oncology and other disease areas.

That kind of institutional validation matters for a company still working toward profitability.

TXG does not currently have a P/E ratio due to negative earnings. Its price-to-sales ratio sits at 6.27, which is considered elevated compared to historical averages — suggesting the stock may be priced for growth that hasn’t yet arrived.

A Look at the Financials

GF Score for TXG stands at 69 out of 100, indicating moderate long-term return potential. Financial strength scores well at 8/10, but profitability ranks just 3/10.

The company carries a market cap of approximately $4.03 billion.

One flag worth watching: insiders have sold $1.8 million worth of stock over the past three months, with zero insider buying during the same period.

That kind of one-sided insider activity doesn’t automatically signal trouble, but it’s a data point investors tend to notice.

The Cleveland Clinic partnership doesn’t come with revenue figures or a commercialization timeline attached. It’s a research agreement — with potential downstream diagnostic applications if the science holds up.

For now, the market liked the headline.

The post 10X Genomics (TXG) Stock Jumps 4% on Cleveland Clinic Bladder Cancer Partnership appeared first on CoinCentral.